Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
FORT LAUDERDALE - Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company with a market capitalization of $7.65 million, has developed a new series of orally active, non-covalent protease inhibitors showing dose-dependent antiviral activity against SARS-CoV-2 in infected mice, according to a press release issued Thursday. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt, positioning it well for continued research and development efforts.
The research was conducted at the University of Arizona as part of an ongoing collaboration between the pharmaceutical company and the university.
The new compounds target PLpro, a viral enzyme essential for coronavirus replication that also suppresses the human immune system following infection. The company reports these inhibitors are orally active in mice and have demonstrated favorable pharmacokinetics profiles.
"There are still unmet medical needs for agents to combat SARS Coronavirus infections," said Dr. Steve Slilaty, CEO of Sunshine Biopharma, in the statement.
This development follows the company’s previous research on PLpro inhibitors, which was published in the Journal of Medicinal Chemistry in August 2024. The company’s earlier lead compound had shown efficacy in a transgenic mouse model to block SARS-CoV-2 infection.
Sunshine Biopharma currently markets 74 generic prescription drugs in Canada with 12 additional drugs scheduled for launch in 2026. The company is also developing K1.1 mRNA, targeted for liver cancer, alongside its coronavirus research. The company’s revenue has grown by 19.22% over the last twelve months, reflecting its expanding product portfolio. InvestingPro subscribers can access 8 additional key insights about SBFM’s financial health and market position.
The company noted that work is currently in progress to analyze the dose-dependent efficacy of these new molecules in mice infected with SARS-CoV-2. While the stock has shown strong momentum with an 11.25% gain over the past week, InvestingPro data indicates the company maintains a healthy financial position with a current ratio of 5.0, suggesting strong short-term liquidity to support its ongoing research initiatives.
In other recent news, Sunshine Biopharma Inc. has appointed M&K CPAS, PLLC as its new independent auditor. This change follows the unanimous decision by the company’s board of directors and audit committee to dismiss Bush & Associates CPA LLC. Sunshine Biopharma confirmed there were no disagreements with the former auditor concerning accounting principles, financial statement disclosures, or auditing procedures during the fiscal years ending December 31, 2023, and 2024, as well as the interim period through September 24, 2025. These developments were disclosed in a statement based on a recent SEC filing. The company has not provided further details on the reasons for this change. This appointment marks a significant update in the company’s auditing oversight. Investors often consider such changes in auditors as noteworthy, as they can impact the company’s financial reporting and compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.